Genetically determined NLRP3 inflammasome activation associates with systemic inflammation and cardiovascular mortality.
Stefan J SchunkMarcus Edi KleberWinfried MärzShichao PangStephen ZewingerSarah TriemPhilipp EgeMatthias Christian ReichertMarcin KrawczykSusanne N WeberIsabella JaumannDavid SchmitTamim SarakpiStefan WagenpfeilRafael KramannEric BoerwinkleChristie M BallantyneMegan L GroveVinicius TraganteAnna P PilbrowArthur Mark RichardsVicky A CameronRobert N DoughtyMarie-Pierre DubéJean Claude TardifYassamin Feroz-ZadaMaxine SunChang LiuYi-An KoArshed A QuyyumiJaana A HartialaWai Hong Wilson TangStanley L HazenHooman AllayeeCaitrin W McDonoughYan GongRhonda M Cooper-DeHoffJulie A JohnsonMarkus ScholzAndrej TerenRalph BurkhardtAndreas MartinssonJ Gustav SmithLars WallentinStefan K JamesNiclas ErikssonHarvey D WhiteClaes HeldDawn M WaterworthStella TrompetJohan Wouter JukemaIan FordDavid J StottNaveed SattarSharon CresciJohn A SpertusHannah CampbellSascha TierlingJörn WalterEmmanuel AmpofoBarbara A NiemeyerPeter LippHeribert SchunkertMichael BöhmWolfgang KoenigDanilo FliserUlrich LaufsThimoteus Speernull nullnull nullPublished in: European heart journal (2021)
The NLRP3 intronic variant rs10754555 is associated with increased systemic inflammation, inflammasome activation, prevalent coronary artery disease, and mortality. This study provides evidence for a substantial role of genetically driven systemic inflammation in CVD and highlights the NLRP3 inflammasome as a therapeutic target.